Delinia (Series A)
Funding Details
- Awarder
- Inbox
- Date Award
- September 14, 2016
- Vertical
- Biotechnology
- Funding URL
- View Funding Page
- Funding Amount:
- $35,000,000
Company Info
- Company Description
- Delinia was founded to discover and develop novel therapeutics for the treatment of autoimmune and inflammatory diseases. Delinia's lead program is a molecule that selectively potentiates and expands regulatory T cells (Tregs), the powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis.
- Market
- Autoimmune and inflammatory diseases
- Location
- Cambridge, Massachusetts, USA
- Coinvestors
- Atlas Venture, Sofinnova Partners